Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

NCT06017323 | Withdrawn Phase 1 DMC FDA Drug

• 1 other identifier: STUDY00001899
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase I open labelled study to treat patients with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with gemcitabine and nab-paclitaxel given days 1, 8, and 15 every 28 days, and proglumide. This is a phase 1 study with 3+3 design, enrolling3-12 patients over 2 planned dose levels of proglumide(maximum 6 patients per dose level). Proglumide will be tested at the daily dose of 1200 mg orally (PO) given as 400mg three times daily (TID) (dose level 1) or 1600 mg orally(PO) given as 800 mg twice a day (BID) (dose level 2). All cycles are 28 days. Patients will be monitored for safety and toxicity by laboratory blood testing and physical examinations.

Conditions

Metastatic Pancreatic Cancer

Keywords

Proglumide; Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

• Proglumide Recommended Phase II dose and schedule (RP2D)

  Determination of the recommended phase II dose and schedule (RP2D) of proglumide in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

  2 years

Secondary Outcomes (4)

• Overall survival (OS)

  through 2 years after end of treatment

• Progression-free survival

  2 years

• Objective response rate by RECIST v. 1.1

  2 years

• Change in tumor marker (CA19-9)

  2 years

Study Arms (2)

Dose Level 1:Proglumide TID with Gemcitabine and Nab-Paclitaxel

EXPERIMENTAL

Proglumide given three times a day with gemcitabine and nab-paclitaxel

Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Proglumide Dose level 1

Dose Level 2:Proglumide BID with Gemcitabine and Nab-Paclitaxel

EXPERIMENTAL

Proglumide given two times a day with gemcitabine and nab-paclitaxel

Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Proglumide Dose level 2

Interventions

Gemcitabine DRUG

1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)

Also known as: Gemzar

Dose Level 1:Proglumide TID with Gemcitabine and Nab-Paclitaxel; Dose Level 2:Proglumide BID with Gemcitabine and Nab-Paclitaxel

Nab paclitaxel DRUG

125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)

Dose Level 1:Proglumide TID with Gemcitabine and Nab-Paclitaxel; Dose Level 2:Proglumide BID with Gemcitabine and Nab-Paclitaxel

Proglumide Dose level 1 DRUG

Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)

Dose Level 1:Proglumide TID with Gemcitabine and Nab-Paclitaxel

Proglumide Dose level 2 DRUG

Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).

Dose Level 2:Proglumide BID with Gemcitabine and Nab-Paclitaxel

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent and any locally-required authorization (e.g., HIPAA in the USA) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
• Age \> 18 years at time of study entry.
• Adequate normal organ and marrow function as defined below:
• Hemoglobin ≥ 9.0 g/dL
• Absolute neutrophil count (ANC) \> 1500 permm3
• Platelet count ≥100,000 per mm3)
• Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN).
• Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤2.5 x ULN of normal unless liver metastases are present, in which case it must be ≤5x ULN
• Creatinine clearance (CL) \>60 mL/min using the Cockcroft-Gault formula.
• Evidence of post-menopausal status or negative urine or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
• Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments, or if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization(bilateral oophorectomy or hysterectomy).
• Patients must have measurable disease by RECIST v1.1 and disease amenable to serial biopsy.
• Subjects may not have received prior therapy with Gemcitabine (GEM)/Nab-paclitaxel (NAB-P).
• Patients must have metastatic pancreatic ductal adenocarcinoma with adenocarcinoma as the dominant histology (biopsy-proven, primary tumor biopsy is acceptable for eligibility)
• No prior systemic treatment for metastatic disease(neoadjuvant/adjuvant therapy is allowable but could not contain GEM or NAB-P).

You may not qualify if:

• Subjects with a concurrent malignancy or malignancy within 3 years prior to starting study drug, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer, or localized prostate cancer following definitive therapy.
• Subjects with uncontrolled cardiovascular diseases(congestive heart failure, symptoms of coronary artery disease, cardiac arrhythmias) or who have suffered a myocardial infarction in the preceding 6months.
• Blood anticoagulation that cannot be safely stopped for biopsy.
• Subjects with poorly controlled medical conditions including asthma, chronic obstructive pulmonary disease, diabetes, seizure disorders, hepatic or renal failure.
• Pregnant or nursing women.
• Men or women of childbearing potential who are unwilling to employ adequate contraception(condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], or abstinence) prior to study entry, for the duration of study participation, and for 6 months thereafter.
• Any concurrent chemotherapy, Investigational Product (IP), biologic, or hormonal therapy for cancer treatment.
• Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
• History of allogenic organ transplantation.
• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea or inability to digest and absorb pills, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring Adverse Events (AEs) or compromise the ability of the patient to give written informed consent
• Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and Tuberculosis (TB) testing in line with local practice), hepatitis B (HBV) (known positive HBV surface antigen (HBsAg) result), hepatitis C (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies).
• Patients with a past or resolved HBV infection(defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible.
• Patients positive for hepatitis C (HCV)antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
• Testing for tuberculosis, hepatitis B and C and HIV is not a requirement for screening for the clinical trial.
• Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational drug. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.

Sponsors & Collaborators

• Georgetown University: lead

Study Sites (1)

Lombardi Comprehensive Cancer Center, Georgetown University

Washington D.C., District of Columbia, 20007, United States

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Gemcitabine; Taxes

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Economics; Health Care Economics and Organizations

Study Officials

• Benjamin WE, MD

  Georgetown University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2023
• First Posted: August 30, 2023
• Study Start: October 1, 2023
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: October 25, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)